Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) was upgraded by equities researchers at RODMAN&RENSHAW to a "strong-buy" rating in a note issued to investors on Thursday,Zacks.com reports.
Separately, Rodman & Renshaw assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday. They issued a "buy" rating and a $9.00 price objective for the company.
Check Out Our Latest Analysis on Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Trading Up 7.9 %
Shares of NASDAQ:EPRX traded up $0.23 during trading on Thursday, reaching $3.13. The company had a trading volume of 15,382 shares, compared to its average volume of 15,384. The company has a fifty day moving average of $2.66 and a two-hundred day moving average of $2.68. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $5.58. The stock has a market capitalization of $85.39 million and a P/E ratio of -4.35.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC purchased a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,000 shares of the company's stock, valued at approximately $34,000.
Eupraxia Pharmaceuticals Company Profile
(
Get Free Report)
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Further Reading
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
